CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (109)	8/15/1998 9:20:00 PM
From: Pseudo Biologist	Read Replies (1) of 666

Rick, here is a link to something a posted to the TCLN thread earlier: Message 5505774 Includes a link to preclinical work on (some form of?) TNT. Would really like to believe there is more than that, but my quick-and- dirty medline search failed to dig it out. The other link, to a recent perspective in NEJM, cites work by TCLN advisors Dvorak and Thorpe. Interestingly, some of the other references to work using peptides for targeting may have some implication (purely at the speculative level) to Coulter's TAP program: still, I know of no connection whatever between the authors of that report (Wadih Arap, Renata Pasqualini, Erkki Ruoslahti in Science VOL. 279 , 16 JANUARY 1998, 377) and Coulter. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next